Publication of Cancellation of Entries for Kinds of Medical Devices from the Australian Register of Therapeutic Goods – TSJ Industries - 191129

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves to regulate therapeutic goods, including medical devices, ensuring that they meet safety, quality, and efficacy standards. The 2012 amendment, specifically Section 41GP, was introduced to address the need for more stringent controls and transparency in the regulation of medical devices within Australia. This particular legislative action aims to protect public health by enforcing compliance among manufacturers and sponsors of medical devices, ensuring that they provide accurate and necessary information regarding their products. The policy objective behind this amendment is to maintain a high standard of therapeutic goods available in the Australian market, thereby safeguarding consumer safety and health. Under this legislative framework, the delegate of the Secretary to the Department of Health and Ageing has the authority to publish details of the cancellation of entries for kinds of medical devices from the Australian Register of Therapeutic Goods. The cancellation of an entry, as seen in the example of the reusable hot/cold pack manufactured by Hirakawa Corp and sponsored by TSJ Industries, is executed when the sponsor fails to comply with regulatory requirements, such as providing requisite information as mandated by the Act. This specific cancellation, effective from 15 November 2012, highlights the enforcement of compliance and the commitment to upholding the quality and safety standards of therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989, specifically section 41GP, outlines the procedures for the cancellation of entries for kinds of medical devices from the Australian Register of Therapeutic Goods. This Act applies to entities involved in the manufacture, sponsorship, or distribution of medical devices within Australia. The geographic and jurisdictional reach of this Act is national, ensuring that all medical devices within the Australian jurisdiction comply with the stipulated regulations and standards. The Act's provisions extend to all kinds of medical devices, including their manufacture, importation, supply, and advertisement. However, the Act does not apply to personal use of therapeutic goods, which is generally excluded from its scope. Any exclusions, exemptions, or thresholds are defined within the Act and may be further elaborated through subordinate instruments issued under its authority. This ensures that the Act's application can be adapted to changing circumstances and technological advancements in the medical device industry.

Key Provisions

The main operative sections of this legislation, specifically Section 41GP of the Therapeutic Goods Act 1989, mandate the publication of the cancellation of entries for certain kinds of medical devices from the Australian Register of Therapeutic Goods (ARTG). In this instance, the cancellation pertains to a reusable hot/cold compress pack, with an ARTG number 191129, manufactured by Hirakawa Corp and sponsored by TSJ Industries. The cancellation was published by Irina Tsyganova, a delegate of the Secretary to the Department of Health and Ageing, on 12 October 2012, with the cancellation taking effect on 15 November 2012. The reason for the cancellation is the sponsor's failure to comply with a notice under Section 41JA of the Act, which required the provision of specific information related to the medical device in question. Under this Act, the primary obligations imposed on the parties involved, particularly the sponsor, include the responsibility to provide accurate and complete information about the medical device in question. The sponsor must ensure compliance with any notices or requirements issued under the Act, including those stipulated in Section 41JA. Failure to meet these obligations can result in the cancellation of the device's entry from the ARTG, as observed in this case. The manufacturer, Hirakawa Corp, also has a vested interest in ensuring the accuracy of the information provided by the sponsor, as the reputation and marketability of their product are at stake. In terms of the consequences of non-compliance, Section 41GP of the Act provides for the cancellation of the medical device's entry from the ARTG. This cancellation can have significant implications for the sponsor and manufacturer, as it may impact the device's ability to be legally marketed, supplied, or advertised within Australia. Furthermore, the Act does not explicitly state the maximum penalties for non-compliance in this specific context. However, under the broader provisions of the Therapeutic Goods Act 1989, breaches of the Act can result in substantial fines and, in some cases, criminal charges. The exact penalties depend on the nature and severity of the offence, with maximum penalties varying according to the specific provisions of the Act being breached.